Abstract
Anti-cytokine therapy has promoted a revolution in the treatment of several inflammatory disorders during the past 10 years. Despite their medical and commercial success, they exhibit several drawbacks: difficulties of production, excessive costs, and a few side-effects. A promising alternative to the passive infusion of monoclonal antibodies or soluble cytokine receptors is the use of the active anti-cytokine immune therapy (ACIT). Surprisingly, clinical studies suggested the interest of this approach during the late 1980s, even before the advent of anti-cytokine passive immunotherapy. In this review, we first explain the involvement of several cytokines in many common diseases involving cytokine overproduction, and identify key targets for anti-cytokine treatments. We then present an update on current advances in preclinical and clinical development of passive anti-cytokine therapeutic approaches. We further discuss progresses in the promising field of active anti-cytokine immunotherapy. Cytokine receptors biologics and small molecules developed using structure/function information, which also constitute important options for treating the cytokine-mediated diseases, are not discussed in this review.
Keywords: Anti-cytokine therapy, asthma, autoimmunity, cancer, cytokines, diabetes, immune-mediated inflammatory disease, inflammatory bowel disease, multiple sclerosis, psoriasis
Current Pharmaceutical Design
Title: Anti-Cytokine Therapeutics: History and Update
Volume: 15 Issue: 17
Author(s): Rojo A. Ratsimandresy, Jay Rappaport and Jean-Francois Zagury
Affiliation:
Keywords: Anti-cytokine therapy, asthma, autoimmunity, cancer, cytokines, diabetes, immune-mediated inflammatory disease, inflammatory bowel disease, multiple sclerosis, psoriasis
Abstract: Anti-cytokine therapy has promoted a revolution in the treatment of several inflammatory disorders during the past 10 years. Despite their medical and commercial success, they exhibit several drawbacks: difficulties of production, excessive costs, and a few side-effects. A promising alternative to the passive infusion of monoclonal antibodies or soluble cytokine receptors is the use of the active anti-cytokine immune therapy (ACIT). Surprisingly, clinical studies suggested the interest of this approach during the late 1980s, even before the advent of anti-cytokine passive immunotherapy. In this review, we first explain the involvement of several cytokines in many common diseases involving cytokine overproduction, and identify key targets for anti-cytokine treatments. We then present an update on current advances in preclinical and clinical development of passive anti-cytokine therapeutic approaches. We further discuss progresses in the promising field of active anti-cytokine immunotherapy. Cytokine receptors biologics and small molecules developed using structure/function information, which also constitute important options for treating the cytokine-mediated diseases, are not discussed in this review.
Export Options
About this article
Cite this article as:
Ratsimandresy A. Rojo, Rappaport Jay and Zagury Jean-Francois, Anti-Cytokine Therapeutics: History and Update, Current Pharmaceutical Design 2009; 15 (17) . https://dx.doi.org/10.2174/138161209788453130
DOI https://dx.doi.org/10.2174/138161209788453130 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanocrystals: From Raw Material to the Final Formulated Oral Dosage Form - A Review
Current Pharmaceutical Design Protease Inhibitors in the Clinic
Medicinal Chemistry PPARα/HNF4α Interplay on Diversified Responsive Elements. Relevance in the Regulation of Liver Peroxisomal Fatty Acid Catabolism
Current Drug Metabolism Nutrition and Bone Health: Its Relationship to Osteoporosis
Current Nutrition & Food Science Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Treatment Strategies for Fatty Liver Diseases
Reviews on Recent Clinical Trials Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Metabolism in Patients with Rheumatoid Arthritis: Resting Energy Expenditure, Physical Activity and Diet-Induced Thermogenesis. Invited Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews CD4+CD25+ Regulatory T-Cell Therapy for Allergy, Autoimmune Disease and Transplant Rejection
Inflammation & Allergy - Drug Targets (Discontinued) Immunological Targets in Inflammation from the Small Molecule Perspective
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry lncRNA HOTAIR, HOXC11 and HOXC12 Gene Expressions are Upregulated in CaCo2 Cells Treated with P31-43 Toxic Peptide
Current Signal Transduction Therapy Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Effectiveness and Tolerability of Very-low Volume Preparation for Colonoscopy: A Narrative Review
Current Drug Metabolism Cancer and Treatment Modalities
Current Cancer Therapy Reviews Editorial [Hot Topic: Natural Compounds as Cancer Chemopreventive and Chemotherapeutic Agents: Insights Gained from Mechanistic and Pharmacologic Studies]
Anti-Cancer Agents in Medicinal Chemistry Challenges in Oral Delivery: Role of P-gp Efflux Pump
Current Drug Therapy The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Culture Supernatants from Lactobacillus plantarum Induce Necrosis on a Human Promyelocytic Leukemia Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets